1-4

認知症　参考文献

・Larson EB, Kukull WA, Buchner D, et al:Ad- verse drug reactions associated with global cognitive impairment in elderly persons. Ann Int Med 107:169-173, 1987

・Mizukami K, Hatanaka K, Tanaka Y, et al: Therapeutic effects of the selective serotonin noradrenalin reuptake inhibitor milnacipran on depressive symptoms in patients with Alz- heimer’s disease. Prog Neuro-Psychopharmacol Biol Psychiatry 33:349-352, 2009

・高橋晶，水上勝義，朝田隆:レビー小体型認知症(DLB)の前駆症状，初期症状.老年精神医学雑誌 22(増刊):60-64, 2011

・Gauthier S, Feldman H, Hecker J, et al:Effica- cy of donepezil on behavioral symptoms in pa- tients with moderate to severe Alzheimer’s disease. Int Psychogeriatr 14:389-404, 2002

・Tanaka M, Namiki C, Thuy DH, et al:Predic- tion of psychiatric response to donepezil in pa- tients with mild to moderate Alzheimer’s dis- ease. J Neurol Sci 225:135-141, 2004

・Lyketsos CG, DelCampo L, Steinberg M, et al: Treating depression in Alzheimer disease: effi- cacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Arch Gen Psychiatry 60:737-746, 2003

・Takahashi S, Mizukami K, Yasuno F, et al: Depression associated with dementia with Lewy bodies (DLB) and the effect of somato- therapy. Psychogeriatrics 9:56-61, 2009

・Mori S, Mori E, Iseki E, et al:Efficacy and safety of donepezil in patients with dementia with Lewy bodies: Preliminary findings from an openlabel study. Psychiatry Clin Neurosci 60:190-195, 2006

・Mori T, Ikeda M, Fukuhara R, et al:Correla- tion of visual hallucinations with occipital rCBF changes by donepezil in DLB. Neurology 66: 935-937, 2006

・Iwasaki K, Maruyama M, Tomita N, et al:Ef- fects of the traditional Chinese medicine Yi- Gan San for cholinesterase inhibitor-resistant visual hallucinations and neuropsychiatric symptoms in patients with dementia with Lewy bodies. J Clin Psychiatry 66:1612 – 1613 , 2005

・Shigenobu K, Ikeda M, Fukuhara R, et al:Re- ducing the burden of caring for Alzheimer’s disease through the amelioration of “delusions of theft” by drug therapy. Int J Geriatr Psychia- try 17:211-217, 2002

・Mizukami K, Asada T, Kinoshita T, et al:A Randomized Crossover Study of a Traditional Japanese Medicine (Kampo)“Yokukansan”in the Treatment of the Behavioral and Psycho- logical Symptoms of Dementia. Int J Neuropsy- chopharmacol 12:191-199, 2009

・Schneider LS, Dagerman KS, Insel P:Risk of death with atypical antipsychotic drug treat- ment for dementia: meta-analysis of random- ized placebocontrolled trials. J Am Med Assoc 294:1934-1943, 2005

・原敬二郎:老人患者の情緒障害に対する抑肝散およびその加味方の効果について.日本東洋医学雑誌 35:49-54, 1984

・Iwasaki K, Satoh-Nakagawa T, Maruyama M, et al:Randomized, observer-blind, controlled trial of the traditional Chinese medicine Yi-Gan San for improvement of behavioral and psycho- logical symptoms and activities of daily living in dementia patients. J Clin Psychiatry 66: 248-252, 2005

・水上勝義，畑中公孝，田中芳郎，他:認知症にみられる周辺症状に対する抑肝散の効果について-17自験例の検討から-.漢方医学 33: 419-422, 2009

・Mizukami K:Kampo therapy as an alternative to pharmacotherapy using antipsychotic medi- cines for behavioral and psychological symp- toms of dementia (BPSD). Psychogeriatrics 8: 137-141, 2008

・Terasawa K, Shimada Y, Kita T:Choto-san in the treatment of vascular dementia: a double- blind, placebo-controlled study. Phytomedicine 4:15-22, 1997

・大友英一，東儀英夫，小暮久也，他:脳血管障害に対するツムラ黄連解毒湯の臨床的有用性. Ca hopantenate を対照とした封筒法による Well controlled study.Geriat Med 29:121 – 151, 1991

・堀口淳，秋田清実，塩田一雄，他:痴呆患者のせん妄や情動障害に対するバルプロ酸の治療効果.精神医学 39:189-191, 1997

・Mizukami K, Hatanaka K, Ishii T, et al:A low dose of sodium valproate in the treatment of outpatients with behavioral and psychological symptoms of dementia. Geriatr Gerontol Int 10:324-326, 2010

・Cantillon M, Brunswick R, Molina D, et al: Buspirone vs. haloperidol: a double-blind trial for agitation in a nursing home population with Alzheimer’s disease. Am J Geriat Psychiatry 4:263-267, 1996

・Sato S, Mizukami K, Asada T:A preliminary open-label study of 5 -HT 1 A partial agonist tandospirone for behavioural and psychological symptoms associated with dementia. Prog Neu- ropsychopharmacol Biol Psychiatry 10:281 -283, 2007

・De Deyn PP, Rabheru K, Rasmussen A, et al:A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of demen- tia. Neurology 53:946-955, 1999

・Katz IR, Jeste DV, Mintzer JE, et al:Compari- son of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Ris- peridone Study Group. J Clin Psychiatry 60: 107-115, 1999

・Clark WS, Street JS, Feldman PD, et al:The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer’s disease. J Clin Psychiatry 62:34 – 40, 2001

・Tariot PN, Ismail MS:Use of quetiapine in el- derly patients. J Clin Psychiatry 63 (Suppl 13):21-26, 2002

・Rainer M, Haushofer M, Pfolz H, et al:Quetia- pine versus risperidone in elderly patients with behavioural and psychological symptoms of de- mentia: efficacy, safety and cognitive function. Eur Psychiatry 22:395-403, 2007

・Sato S, Mizukami K, Moro K, et al:Efficacy of perospirone in the management of aggressive behavior associated with dementia. Prog Neu- ropsychopharmacol Biol Psychiatry 30:679 – 683, 2006

・切池信夫，井上幸紀，奥野正景，他:初老期および老年痴呆，脳血管障害に伴う異常行動，せん妄に対するチアプリドの有用性.Geriat Med 30:655-661, 1992

・國芳雅広，松岡稔昌，稲永和豊，他:高齢者のせん妄に対するリスペリドンの臨床効果.臨床と研究 75:1452-1454, 1998

・浅井清剛，東麻衣子，石塚卓也，他:せん妄に対するSerotonin-Dopamine Antagonist(SDA) の有用性.精神医学 46:179-182, 2004

・松原敏郎 , 河合宏治 , 兼行浩史，他:高齢者のせん妄に対する低用量のクエチアピンの使用経験.精神医学 51:49-55, 2009

・伊藤嘉浩:老人福祉施設におけるせん妄を中心とした痴呆随伴症状に対する perospironeの効果.臨床精神薬理 7:981-990, 2004

・Ikeda M, Shigenobu K, Fukuhara R, et al:Effi- cacy of fluvoxamine as a treatment for behav- ioral symptoms in frontotemporal lobar degen- eration patients. Dement Geriatr Cogn Disord 17:117-121, 2004

・Kimura T, Hayashida H, Furukawa H, et al: Pilot study of pharmacological treatment for frontotemporal dementia: effect of Yokukansan on behavioral symptoms. Psychiatry Clin Neu- rosci 64:207-210, 2010

・藤城弘樹. 老年精神医学雑誌 2016; 27（Suppl. 1）: 96-102

・Ferman TJ et al. Parkinsonism Relat Disord. 2013; 19（2）: 227-231

・井関栄三. 精神医学 2007; 49（7）: 691-69

・認知症の新しい診療ガイドラインについてA new diagnostic guideline for dementia　冨本秀和

日老医誌 2018;55:169―177

・Olazarán J, Reisberg B, Clare L, Cruz I, Peña-Casanova J, Del Ser T, Woods B, Beck C, Auer S, Lai C, Spector A, Fazio S, Bond J, Kivipelto M, Brodaty H, Rojo JM, Collins H, Teri L, Mittelman M, Orrell M, Feldman HH, Muñiz R. Nonpharmacological therapies in Alzheimer’s disease: a systematic review of efficacy. Dement Geriatr Cogn Disord. 2010; 30(2): 161-78. doi: 10.1159/000316119.

・ Woods B, Aguirre E, Spector AE, Orrell M. Cognitive stimulation to improve cognitive functioning in people with dementia. Cochrane Database Syst Rev. 2012; 2: CD005562. doi: 10.1002/14651858.CD005562.pub2.

・ Bahar-Fuchs A, Clare L, Woods B. Cognitive training and cognitive rehabilitation for mild to moderate Alzheimer’s disease and vascular dementia. Cochrane Database Syst Rev. 2013; 6: CD003260. doi: 10.1002/14651858.CD003260.pub2.

・Alves J, Magalhães R, Thomas RE, Gonçalves OF, Petrosyan A, Sampaio A. Is there evidence for cognitive intervention in Alzheimer disease? A systematic review of efficacy, feasibility, and cost-effectiveness. Alzheimer Dis Assoc Disord. 2013; 27(3): 195-203. doi: 10.1097/WAD.0b013e31827bda55.

・ Clare L, Linden DE, Woods RT, Whitaker R, Evans SJ, Parkinson CH, van Paasschen J, Nelis SM, Hoare Z, Yuen KS, Rugg MD. Goal-oriented cognitive rehabilitation for people with early- stage Alzheimer disease: a single-blind randomized controlled trial of clinical efficacy. Am J Geriatr Psychiatry. 2010; 18(10): 928-39. doi: 10.1097/JGP.0b013e3181d5792a.

・ Thivierge S, Jean L, Simard M. A randomized cross-over controlled study on cognitive rehabilitation of instrumental activities of daily living in Alzheimer disease. Am J Geriatr Psychiatry. 2014; 22(11): 1188-99. doi: 10.1016/j.jagp.2013.03.008.

・ Woods B, Spector AE, Jones CA, Orrell M, Davies SP. Reminiscence therapy for dementia. Cochrane Database Syst. Rev. 2005; 2: CD001120. DOI: 10.1002/14651858.CD001120.pub2. (Woods B, Spector A, Jones C, Orrell M, Davies S. Reminiscence therapy for dementia. Cochrane Dementia and Cognitive Improvement Group, Cochrane Database Syst. Rev. 2009; 1)

・Cotelli M, Manenti R, Zanetti O. Reminiscence therapy in dementia: a review. Maturitas. 2012; 72(3): 203-5. doi: 10.1016/j.maturitas.2012.04.008.

・ Subramaniam P, Woods B. The impact of individual reminiscence therapy for people with dementia: systematic review. Expert Rev Neurother. 2012; 12(5): 545-55. doi: 10.1586/ern.12.35.

・Huang HC, Chen YT, Chen PY, Huey-Lan Hu S, Liu F, Kuo YL, Chiu HY. Reminiscence Therapy Improves Cognitive Functions and Reduces Depressive Symptoms in Elderly People With Dementia: ・A Meta-Analysis of Randomized Controlled Trials. J Am Med Dir Assoc. 2015; 16(12): 1087-94. doi: 10.1016/j.jamda.2015.07.010.

・Rolland Y, Pillard F, Klapouszczak A, Reynish E, Thomas D, Andrieu S, Rivière D, Vellas B. Exercise program for nursing home residents with Alzheimer’s disease: a 1-year randomized, controlled trial. J Am Geriatr Soc. 2007 Feb;55(2):158-65.

・ Pitkälä K, Savikko N, Poysti M, Strandberg T, Laakkonen ML. Efficacy of physical exercise intervention on mobility and physical functioning in older people with dementia: a systematic review. Exp Gerontol. 2013; 48(1): 85-93. doi: 10.1016/j.exger.2012.08.008.

・Forbes D, Forbes SC, Blake CM, Thiessen EJ, Forbes S. Exercise programs for people with dementia. Cochrane Database Syst. Rev. 2015; 4: CD006489. doi: 10.1002/14651858.CD006489.pub4.

・ Farina N, Rusted J, Tabet N. The effect of exercise interventions on cognitive outcome in

Alzheimer’s disease: a systematic review. Int Psychogeriatr. 2014; 26(1): 9-18. doi:

10.1017/S1041610213001385.

・ Vink AC, Bruinsma MS, Scholten RJPM. Music therapy for people with dementia. Cochrane

Database Syst. Rev. 2004; 3: CD003477. doi: 10.1002/14651858.CD003477.pub2. (Vink AC, Bruinsma MS, Scholten RJPM. Music therapy for people with dementia. Cochrane Database Syst. Rev. 2013; 9)

・ Ueda T, Suzukamo Y, Sato M, Izumi S. Effects of music therapy on behavioral and psychological symptoms of dementia: a systematic review and meta-analysis. Ageing Res Rev. 2013; 12(2): 628-41. doi: 10.1016/j.arr.2013.02.003.

・ Salami O, Lyketsos C, Rao V. Treatment of sleep disturbance in Alzheimer’s dementia. Int J Geriatr Psychiatry. 2011; 26(8): 771-82. doi: 10.1002/gps.2609.

・ Forbes D, Blake CM, Thiessen EJ, Peacock S, Hawranik P. Light therapy for improving cognition, activities of daily living, sleep, challenging behavior, and psychiatric disturbances in dementia. Cochrane Database Syst. Rev. 2014; 2: CD003946. doi: 10.1002/14651858.CD003946.pub4.

・World Health Organization: International Classification of Diseases. And Related Heath Problems, 10th Revision, World Health Organization, Geneva, 1993.

・American Psychiatric Association: Diagnostic and Statis- tical Manual of Mental disorders, Fourth Edition. Text Revision, American Psychiatric Association, Washing- ton, DC, 2000.

・McKhann GM, Knopman DS, Chertkow H, et al.: The di- agnosis of dementia due to Alzheimer’s disease: Recom- mendations from the National Institute on Aging- Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7: 263―269.

・American Psychiatric Association: Diagnostic and statis-tical manual of mental disorders, Fourth Edition, American Psychiatric Association, Washington, DC, 1994.

・McKhann G, Drachman D, Folstein M, et al.: Clinical di- agnosis of Alzheimer’s disease: Report of the NINCDS- ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Al-zheimer’s Disease. Neurology 1984; 34: 939―944.

・Albert MS, DeKosky ST, Dickson D, et al.: The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendation from the National Institute on Aging- Alzheimer’s association workgroups on diagnostic guide- lines for Alzheimer’s disease. Alzheimers Dement 2011;

7: 270―279.

・Sperling RA, Aisen PS, Beckett LA, et al.: Toward the

preclinical stages of Alzheimer’s disease: Recommenda- tion from the National Institute on Aging-Alzheimer’s association workgroups on diagnostic guidelines for Al- zheimer’s disease. Alzheimers Dement 2011; 7: 280―292.

・Dubois B, Feldman HH, Jacova C, et al.: Revising the defi- nition of Alzheimer’s disease;A new lexicon. Lancet Neu- rol 2010; 9: 118―1127.

・「かかりつけ医のためのＢＰＳＤに対応する向精神薬使用ガイドライン（第２版）」

・高齢者の安全な薬物療法ガイドライン2015日本老年医学会

・認知症疾患治療ガイドライン2010認知症疾患治療ガイドライン作成合同委員会

・BPSD初期対応ガイドライン2012.精神症状・行動異常を示す認知症患者の初期対応の指針作成研究班

・睡眠薬の適正使用ガイドライン2014.睡眠薬の適正使用および減量・中止のための診療ガイドラインに関する研究班

・超高齢社会におけるかかりつけ医のための適正処方の手引き 2. 認知症発行公益社団法人日本医師会

・Tolosa E, Litvan I, Hoglinger GU, et al. A phase 2 trial of the

GSK-3 inhibitor tideglusib in progressive supranuclear palsy.

Mov Disord 2014;29:470-478.

・Hoglinger GU, Huppertz HJ, Wagenpfeil S, et al. Tideglusib

reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial. Mov Disord 2014;29: 479-487.

・饗場郁子.Corticobasal syndrome 最近の進歩と今後の課題.Brain Nerve 2012;64:462-473.

・下畑享良，西澤正豊.CBS の臨床.Brain Nerve 2013;65:31-40. 16)Lang AE, Riley DE, Bergeron C. Cortico-basal ganglionicdegeneration. Neurodegenerative diseases 1994; Philadelphia:WB Saunders: 877-894.

・Brain bank. 神経疾患ブレインバンク [Internet]. 東京:ブレインバンク研究班事務局;2010 Jan 1. [cited 2015 Nov 16]. Available from: http://www.brain-bank.org/brain-bank/index.html. Japanese.

・Tartaglia MC, Sidhu M, Laluz V, et al. Sporadic corticobasal syndrome due to FTLD-TDP. Acta Neuropathol 2010;119:365- 374.

・齊藤祐子，足立正，村山繁雄:【タウオパチー非アルツハイマー型認知症を探る】その他の孤発性タウオパチー嗜銀顆粒性認知症.Clinical Neuroscience 2009; 27: 325―327.

・齊藤祐子，徳丸阿耶，金丸和富，石井賢二，足立正，崎山快夫ほか:【アルツハイマー型認知症の諸問題を再考する】認知症の早期診断を多角的に考える神経病理所見からみた臨床診断のポイント高齢者タウオパチーの診断のポイント.老年精神医学雑誌 2011; 22: 36―44.

・山田正仁:【前頭側頭型痴呆をめぐって】神経原線維変化型老年痴呆(辺縁系神経原線維変化型痴呆).Clinical Neuroscience 2005; 23: 332―334.

・山田正仁:【タウオパチー非アルツハイマー型認知症を探る】その他の孤発性タウオパチー神経原線維変化型老年期認知症石灰沈着を伴うびまん性神経原線維変化病.Clinical Neuroscience 2009; 27: 328―330.

	眼科	脳神経外科
現在の呼び出し番号
現在の待ち人数

脳疾患を知る

・Larson EB, Kukull WA, Buchner D, et al:Ad- verse drug reactions associated with global cognitive impairment in elderly persons. Ann Int Med 107:169-173, 1987

・Mizukami K, Hatanaka K, Tanaka Y, et al: Therapeutic effects of the selective serotonin noradrenalin reuptake inhibitor milnacipran on depressive symptoms in patients with Alz- heimer’s disease. Prog Neuro-Psychopharmacol Biol Psychiatry 33:349-352, 2009

・高橋 晶，水上勝義，朝田 隆:レビー小体型 認知症(DLB)の前駆症状，初期症状.老年精神 医学雑誌 22(増刊):60-64, 2011

・Gauthier S, Feldman H, Hecker J, et al:Effica- cy of donepezil on behavioral symptoms in pa- tients with moderate to severe Alzheimer’s disease. Int Psychogeriatr 14:389-404, 2002

・Tanaka M, Namiki C, Thuy DH, et al:Predic- tion of psychiatric response to donepezil in pa- tients with mild to moderate Alzheimer’s dis- ease. J Neurol Sci 225:135-141, 2004

・Lyketsos CG, DelCampo L, Steinberg M, et al: Treating depression in Alzheimer disease: effi- cacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Arch Gen Psychiatry 60:737-746, 2003

・Takahashi S, Mizukami K, Yasuno F, et al: Depression associated with dementia with Lewy bodies (DLB) and the effect of somato- therapy. Psychogeriatrics 9:56-61, 2009

・Mori S, Mori E, Iseki E, et al:Efficacy and safety of donepezil in patients with dementia with Lewy bodies: Preliminary findings from an openlabel study. Psychiatry Clin Neurosci 60:190-195, 2006

・Mori T, Ikeda M, Fukuhara R, et al:Correla- tion of visual hallucinations with occipital rCBF changes by donepezil in DLB. Neurology 66: 935-937, 2006

・Iwasaki K, Maruyama M, Tomita N, et al:Ef- fects of the traditional Chinese medicine Yi- Gan San for cholinesterase inhibitor-resistant visual hallucinations and neuropsychiatric symptoms in patients with dementia with Lewy bodies. J Clin Psychiatry 66:1612 – 1613 , 2005

・Shigenobu K, Ikeda M, Fukuhara R, et al:Re- ducing the burden of caring for Alzheimer’s disease through the amelioration of “delusions of theft” by drug therapy. Int J Geriatr Psychia- try 17:211-217, 2002

・Mizukami K, Asada T, Kinoshita T, et al:A Randomized Crossover Study of a Traditional Japanese Medicine (Kampo)“Yokukansan”in the Treatment of the Behavioral and Psycho- logical Symptoms of Dementia. Int J Neuropsy- chopharmacol 12:191-199, 2009

・Schneider LS, Dagerman KS, Insel P:Risk of death with atypical antipsychotic drug treat- ment for dementia: meta-analysis of random- ized placebocontrolled trials. J Am Med Assoc 294:1934-1943, 2005

・原敬二郎:老人患者の情緒障害に対する抑肝散 およびその加味方の効果について.日本東洋医学雑誌 35:49-54, 1984

・Iwasaki K, Satoh-Nakagawa T, Maruyama M, et al:Randomized, observer-blind, controlled trial of the traditional Chinese medicine Yi-Gan San for improvement of behavioral and psycho- logical symptoms and activities of daily living in dementia patients. J Clin Psychiatry 66: 248-252, 2005

・水上勝義，畑中公孝，田中芳郎，他:認知症に みられる周辺症状に対する抑肝散の効果につい て-17自験例の検討から-.漢方医学 33: 419-422, 2009

・Mizukami K:Kampo therapy as an alternative to pharmacotherapy using antipsychotic medi- cines for behavioral and psychological symp- toms of dementia (BPSD). Psychogeriatrics 8: 137-141, 2008

・Terasawa K, Shimada Y, Kita T:Choto-san in the treatment of vascular dementia: a double- blind, placebo-controlled study. Phytomedicine 4:15-22, 1997

・大友英一，東儀英夫，小暮久也，他:脳血管障 害に対するツムラ黄連解毒湯の臨床的有用性. Ca hopantenate を対照とした封筒法による Well controlled study.Geriat Med 29:121 – 151, 1991

・堀口 淳，秋田清実，塩田一雄，他:痴呆患者のせん妄や情動障害に対するバルプロ酸の治療 効果.精神医学 39:189-191, 1997

・Mizukami K, Hatanaka K, Ishii T, et al:A low dose of sodium valproate in the treatment of outpatients with behavioral and psychological symptoms of dementia. Geriatr Gerontol Int 10:324-326, 2010

・Cantillon M, Brunswick R, Molina D, et al: Buspirone vs. haloperidol: a double-blind trial for agitation in a nursing home population with Alzheimer’s disease. Am J Geriat Psychiatry 4:263-267, 1996

・Sato S, Mizukami K, Asada T:A preliminary open-label study of 5 -HT 1 A partial agonist tandospirone for behavioural and psychological symptoms associated with dementia. Prog Neu- ropsychopharmacol Biol Psychiatry 10:281 -283, 2007

・De Deyn PP, Rabheru K, Rasmussen A, et al:A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of demen- tia. Neurology 53:946-955, 1999

・Katz IR, Jeste DV, Mintzer JE, et al:Compari- son of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Ris- peridone Study Group. J Clin Psychiatry 60: 107-115, 1999

・Clark WS, Street JS, Feldman PD, et al:The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer’s disease. J Clin Psychiatry 62:34 – 40, 2001

・Tariot PN, Ismail MS:Use of quetiapine in el- derly patients. J Clin Psychiatry 63 (Suppl 13):21-26, 2002

・Rainer M, Haushofer M, Pfolz H, et al:Quetia- pine versus risperidone in elderly patients with behavioural and psychological symptoms of de- mentia: efficacy, safety and cognitive function. Eur Psychiatry 22:395-403, 2007

・Sato S, Mizukami K, Moro K, et al:Efficacy of perospirone in the management of aggressive behavior associated with dementia. Prog Neu- ropsychopharmacol Biol Psychiatry 30:679 – 683, 2006

・切池信夫，井上幸紀，奥野正景，他:初老期お よび老年痴呆，脳血管障害に伴う異常行動，せん妄に対するチアプリドの有用性.Geriat Med 30:655-661, 1992

・國芳雅広，松岡稔昌，稲永和豊，他:高齢者の せん妄に対するリスペリドンの臨床効果.臨床 と研究 75:1452-1454, 1998

・浅井清剛，東麻衣子，石塚卓也，他:せん妄に 対するSerotonin-Dopamine Antagonist(SDA) の有用性.精神医学 46:179-182, 2004

・松原敏郎 , 河合宏治 , 兼行浩史，他:高齢者のせ ん妄に対する低用量のクエチアピンの使用経験.精神医学 51:49-55, 2009

・伊藤嘉浩:老人福祉施設におけるせん妄を中心 とした痴呆随伴症状に対する perospironeの効果.臨床精神薬理 7:981-990, 2004

・Ikeda M, Shigenobu K, Fukuhara R, et al:Effi- cacy of fluvoxamine as a treatment for behav- ioral symptoms in frontotemporal lobar degen- eration patients. Dement Geriatr Cogn Disord 17:117-121, 2004

・Kimura T, Hayashida H, Furukawa H, et al: Pilot study of pharmacological treatment for frontotemporal dementia: effect of Yokukansan on behavioral symptoms. Psychiatry Clin Neu- rosci 64:207-210, 2010

・藤城弘樹. 老年精神医学雑誌 2016; 27（Suppl. 1）: 96-102

・Ferman TJ et al. Parkinsonism Relat Disord. 2013; 19（2）: 227-231

・井関栄三. 精神医学 2007; 49（7）: 691-69

・認知症の新しい診療ガイドラインについてA new diagnostic guideline for dementia 冨本 秀和

日老医誌 2018;55:169―177

・ Woods B, Aguirre E, Spector AE, Orrell M. Cognitive stimulation to improve cognitive functioning in people with dementia. Cochrane Database Syst Rev. 2012; 2: CD005562. doi: 10.1002/14651858.CD005562.pub2.

・ Bahar-Fuchs A, Clare L, Woods B. Cognitive training and cognitive rehabilitation for mild to moderate Alzheimer’s disease and vascular dementia. Cochrane Database Syst Rev. 2013; 6: CD003260. doi: 10.1002/14651858.CD003260.pub2.

・Alves J, Magalhães R, Thomas RE, Gonçalves OF, Petrosyan A, Sampaio A. Is there evidence for cognitive intervention in Alzheimer disease? A systematic review of efficacy, feasibility, and cost-effectiveness. Alzheimer Dis Assoc Disord. 2013; 27(3): 195-203. doi: 10.1097/WAD.0b013e31827bda55.

・ Thivierge S, Jean L, Simard M. A randomized cross-over controlled study on cognitive rehabilitation of instrumental activities of daily living in Alzheimer disease. Am J Geriatr Psychiatry. 2014; 22(11): 1188-99. doi: 10.1016/j.jagp.2013.03.008.

・Cotelli M, Manenti R, Zanetti O. Reminiscence therapy in dementia: a review. Maturitas. 2012; 72(3): 203-5. doi: 10.1016/j.maturitas.2012.04.008.

・ Subramaniam P, Woods B. The impact of individual reminiscence therapy for people with dementia: systematic review. Expert Rev Neurother. 2012; 12(5): 545-55. doi: 10.1586/ern.12.35.

・Rolland Y, Pillard F, Klapouszczak A, Reynish E, Thomas D, Andrieu S, Rivière D, Vellas B. Exercise program for nursing home residents with Alzheimer’s disease: a 1-year randomized, controlled trial. J Am Geriatr Soc. 2007 Feb;55(2):158-65.

・ Pitkälä K, Savikko N, Poysti M, Strandberg T, Laakkonen ML. Efficacy of physical exercise intervention on mobility and physical functioning in older people with dementia: a systematic review. Exp Gerontol. 2013; 48(1): 85-93. doi: 10.1016/j.exger.2012.08.008.

・Forbes D, Forbes SC, Blake CM, Thiessen EJ, Forbes S. Exercise programs for people with dementia. Cochrane Database Syst. Rev. 2015; 4: CD006489. doi: 10.1002/14651858.CD006489.pub4.

・ Farina N, Rusted J, Tabet N. The effect of exercise interventions on cognitive outcome in

Alzheimer’s disease: a systematic review. Int Psychogeriatr. 2014; 26(1): 9-18. doi:

10.1017/S1041610213001385.

・ Vink AC, Bruinsma MS, Scholten RJPM. Music therapy for people with dementia. Cochrane

Database Syst. Rev. 2004; 3: CD003477. doi: 10.1002/14651858.CD003477.pub2. (Vink AC, Bruinsma MS, Scholten RJPM. Music therapy for people with dementia. Cochrane Database Syst. Rev. 2013; 9)

・ Ueda T, Suzukamo Y, Sato M, Izumi S. Effects of music therapy on behavioral and psychological symptoms of dementia: a systematic review and meta-analysis. Ageing Res Rev. 2013; 12(2): 628-41. doi: 10.1016/j.arr.2013.02.003.

・ Salami O, Lyketsos C, Rao V. Treatment of sleep disturbance in Alzheimer’s dementia. Int J Geriatr Psychiatry. 2011; 26(8): 771-82. doi: 10.1002/gps.2609.

・ Forbes D, Blake CM, Thiessen EJ, Peacock S, Hawranik P. Light therapy for improving cognition, activities of daily living, sleep, challenging behavior, and psychiatric disturbances in dementia. Cochrane Database Syst. Rev. 2014; 2: CD003946. doi: 10.1002/14651858.CD003946.pub4.

・World Health Organization: International Classification of Diseases. And Related Heath Problems, 10th Revision, World Health Organization, Geneva, 1993.

・American Psychiatric Association: Diagnostic and Statis- tical Manual of Mental disorders, Fourth Edition. Text Revision, American Psychiatric Association, Washing- ton, DC, 2000.

・McKhann GM, Knopman DS, Chertkow H, et al.: The di- agnosis of dementia due to Alzheimer’s disease: Recom- mendations from the National Institute on Aging- Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7: 263―269.

・American Psychiatric Association: Diagnostic and statis-tical manual of mental disorders, Fourth Edition, American Psychiatric Association, Washington, DC, 1994.

・McKhann G, Drachman D, Folstein M, et al.: Clinical di- agnosis of Alzheimer’s disease: Report of the NINCDS- ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Al-zheimer’s Disease. Neurology 1984; 34: 939―944.

・Albert MS, DeKosky ST, Dickson D, et al.: The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendation from the National Institute on Aging- Alzheimer’s association workgroups on diagnostic guide- lines for Alzheimer’s disease. Alzheimers Dement 2011;

7: 270―279.

・Sperling RA, Aisen PS, Beckett LA, et al.: Toward the

preclinical stages of Alzheimer’s disease: Recommenda- tion from the National Institute on Aging-Alzheimer’s association workgroups on diagnostic guidelines for Al- zheimer’s disease. Alzheimers Dement 2011; 7: 280―292.

・Dubois B, Feldman HH, Jacova C, et al.: Revising the defi- nition of Alzheimer’s disease;A new lexicon. Lancet Neu- rol 2010; 9: 118―1127.

・「かかりつけ医のためのＢＰＳＤに対応する向精神薬使用ガイドライン（第２版）」

・高齢者の安全な薬物療法ガイドライン2015日本老年医学会

・認知症疾患治療ガイドライン2010認知症疾患治療ガイドライン作成合同委員会

・BPSD初期対応ガイドライン2012.精神症状・行動異常を示す認知症患者の初期対応の指針作成研究班

・睡眠薬の適正使用ガイドライン2014.睡眠薬の適正使用および減量・中止のための診療ガイドラインに関する研究班

・超高齢社会におけるかかりつけ医のための適正処方の手引き 2. 認知症発行 公益社団法人 日本医師会

・Tolosa E, Litvan I, Hoglinger GU, et al. A phase 2 trial of the

GSK-3 inhibitor tideglusib in progressive supranuclear palsy.

Mov Disord 2014;29:470-478.

・Hoglinger GU, Huppertz HJ, Wagenpfeil S, et al. Tideglusib

reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial. Mov Disord 2014;29: 479-487.

・高橋晶，水上勝義，朝田隆:レビー小体型認知症(DLB)の前駆症状，初期症状.老年精神医学雑誌 22(増刊):60-64, 2011

・原敬二郎:老人患者の情緒障害に対する抑肝散およびその加味方の効果について.日本東洋医学雑誌 35:49-54, 1984

・水上勝義，畑中公孝，田中芳郎，他:認知症にみられる周辺症状に対する抑肝散の効果について-17自験例の検討から-.漢方医学 33: 419-422, 2009

・大友英一，東儀英夫，小暮久也，他:脳血管障害に対するツムラ黄連解毒湯の臨床的有用性. Ca hopantenate を対照とした封筒法による Well controlled study.Geriat Med 29:121 – 151, 1991

・堀口淳，秋田清実，塩田一雄，他:痴呆患者のせん妄や情動障害に対するバルプロ酸の治療効果.精神医学 39:189-191, 1997

・切池信夫，井上幸紀，奥野正景，他:初老期および老年痴呆，脳血管障害に伴う異常行動，せん妄に対するチアプリドの有用性.Geriat Med 30:655-661, 1992

・國芳雅広，松岡稔昌，稲永和豊，他:高齢者のせん妄に対するリスペリドンの臨床効果.臨床と研究 75:1452-1454, 1998

・浅井清剛，東麻衣子，石塚卓也，他:せん妄に対するSerotonin-Dopamine Antagonist(SDA) の有用性.精神医学 46:179-182, 2004

・松原敏郎 , 河合宏治 , 兼行浩史，他:高齢者のせん妄に対する低用量のクエチアピンの使用経験.精神医学 51:49-55, 2009

・伊藤嘉浩:老人福祉施設におけるせん妄を中心とした痴呆随伴症状に対する perospironeの効果.臨床精神薬理 7:981-990, 2004

・認知症の新しい診療ガイドラインについてA new diagnostic guideline for dementia　冨本秀和

・超高齢社会におけるかかりつけ医のための適正処方の手引き 2. 認知症発行公益社団法人日本医師会

・齊藤祐子，足立正，村山繁雄:【タウオパチー非アルツハイマー型認知症を探る】その他の孤発性タウオパチー嗜銀顆粒性認知症.Clinical Neuroscience 2009; 27: 325―327.

・山田正仁:【前頭側頭型痴呆をめぐって】神経原線維変化型老年痴呆(辺縁系神経原線維変化型痴呆).Clinical Neuroscience 2005; 23: 332―334.

・山田正仁:【タウオパチー非アルツハイマー型認知症を探る】その他の孤発性タウオパチー神経原線維変化型老年期認知症石灰沈着を伴うびまん性神経原線維変化病.Clinical Neuroscience 2009; 27: 328―330.